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Abstract  
The lung in cystic fibrosis (CF) is home to numerous pathogens that shorten the lives of patients. The aim 
of the present study was to assess changes in the lung bacteriome following antibiotic therapy targeting 
Pseudomonas aeruginosa in children with CF. The study included nine children (9-18 years) with CF 
who were treated for their chronic or intermittent positivity for Pseudomonas aeruginosa. The 
bacteriomes were determined in 16 pairs of sputa collected at the beginning and at the end of a course of 
intravenous antibiotic therapy via deep sequencing of the variable region 4 of the 16S rRNA gene, and the 
total bacterial load and selected specific pathogens were assessed using quantitative real-time PCR. The 
effect of anti-pseudomonal antibiotics was observable as a profound decrease in the total 16S rDNA load 
(p = 0.001) as well as in a broad range of individual taxa including Staphylococcus aureus (p = 0.03) and 
several members of the Streptococcus mitis group (S.oralis, S. mitis, and S. infantis) (p = 0.003). 
Improvements in forced expiratory volume (FEV1) were associated with an increase in Granulicatella sp. 
(p=0.004), whereas a negative association was noted between the total bacterial load and white blood cell 
count (p=0.007). In conclusion, the data show how microbial communities differ in reaction to anti-
pseudomonal treatment, suggesting that certain rare species may be associated with clinical parameters. 
Our work also demonstrates the utility of absolute quantification of bacterial load in addition to the 16S 
rDNA profiling.  
 
Key words: lung bacteriome; antibiotic therapy; cystic fibrosis; Pseudomonas aeruginosa; clinical 
parameters; children 
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Introduction 
Cystic fibrosis (CF) is caused by mutations in the gene for Cystic Fibrosis Transmembrane Conductase 
Regulator (CFTR) protein which, among other effects, causes impairments in mucociliary clearance. This 
enables bacteria to become established in the lungs, which leads to a decline in pulmonary function and 
ultimately to respiratory failure. One of the most important CF pathogens is Pseudomonas aeruginosa. 
This species often dominates the CF lung bacteriome not only in adults (Cox et al. 2010; Hauser et al. 
2011) but also in a considerable number of children (Hauser et al. 2011; Li et al. 2005; Pillarisetti et al. 
2011). Once present in the lower airways, it can cause chronic infections that are difficult to treat (Doring 
and Hoiby 2004). However, antibiotic treatment of patients with chronic P. aeruginosa infection 
occasionally improves the patient’s health status, including their lung function, despite the fact that the 
quantity of the pathogen in the lower airways remains seemingly unchanged (Price et al. 2013; Zemanick 
et al. 2013). Pulmonary exacerbations in CF patients are not solely dependent on the presence of P. 
aeruginosa in the lung (Zemanick et al. 2010). Therefore, interest has expanded towards other species 
that may cohabit the lower airways and play either beneficial or harmful roles in the development of the 
CF lung disease (Zemanick et al. 2011). This area is especially important with respect to the lung 
bacteriome during childhood, which is believed to be amenable to changes (Coburn et al. 2015; Li et al. 
2005).  
 
Our study aimed to investigate changes in the lung bacteriome in patients with chronic or intermittent P. 
aeruginosa infection in relation to intravenous antibiotic treatment. The novel aspect of the study design 
was a combination of 16S rDNA profiling with a set of species-specific PCR reactions that allowed us to 
measure changes in the absolute quantity of several bacterial species other than P. aeruginosa.  
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Material and Methods 
Subjects  
All study subjects attended the CF Centre at the Motol University Hospital, Prague, the Czech Republic; 
this centre takes care of more than 200 children and young persons with the disease. The main inclusion 
criterion for the patients was an intermittent or chronic infection by P. aeruginosa (intermittent infections 
were characterized by less than 50% positive samples for P. aeruginosa over the last 12 months, while 
chronic infections were defined with more than 50% of samples for P. aeruginosa over the last 12 
months, as per Leeds criteria (Lee et al. 2003)).  
 
We recruited nine patients (7 females) aged from 9 to 18 years (median age 14.5 years); two of them (1 
female) having intermittent P. aeruginosa infection and the remaining seven having chronic infection. 
The patients had a combined total of 16 courses of antibiotic therapy with a combination of intravenous 
antibiotics. Seven of the courses were indicated for pulmonary exacerbation, while nine were prescribed 
as part of chronic suppressive anti-pseudomonal therapy. Virtually every patient received a different 
cocktail of two or more antibiotics with the aim to control their P. aeruginosa infection. The choice of 
antibiotics (Supplementary Table S1) was based not only on susceptibility test results of the most recent 
P. aeruginosa isolate (Supplementary Table S2, supplementary material S1.1) but also on drug toxicity, 
tolerability and clinical benefit observed upon their previous use (Doring et al. 2012). Patient records of 
inflammatory markers [white blood cell (WBC) count, C-reactive protein (CRP)] and forced expiratory 
volume (FEV1) were also collected (Table S1). The study was run between September 2012 and 
November 2013. A written consent was obtained from all patients or their guardians, and the study was 
approved by the institutional Ethics Committee, University Hospital Motol, Prague on September 19, 
2012, EK-1445/12. 
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Sputum samples 
Spontaneously expectorated sputum was collected on the day when antibiotic therapy started and on the 
last day of antibiotic treatment, hereinafter referred to as “before” and “after” antibiotic therapy. The 
courses of antibiotic therapy lasted from 11 to 21 days (median 13.5 days). Three patients provided a 
single pair of samples covering one course of antibiotic therapy, five patients underwent two courses, and 
one patient had three courses of the therapy. The time interval between multiple applications of 
intravenous antibiotics ranged from 79 to 212 days (median 120 days). We analysed a total of 32 samples, 
and they were also investigated by routine culture-based microbiological methods and microscopically 
validated as lower airways samples.  
 
DNA extraction 
An aliquot of sputum was frozen immediately upon expectoration. When thawed, it was liquefied with a 
mixture of saline with 46 mmol/L KH2PO4, 32 mmol/L NaOH and 0.9 mg/mL acetylcysteine (Hexal AG, 
Holzkirchen, Germany) and centrifuged. The bacterial pellet was pre-treated by incubation with 50 µg 
lysostaphin (Sigma-Aldrich, St. Louis, MO, USA) for 1 h at 37°C, followed by incubation with proteinase 
K; DNA was then extracted using a QIAamp DNA kit (Qiagen, Hilden, Germany). The extraction 
efficiency was checked by adding a plasmid containing a fragment of Arabidopsis thaliana DNA as an 
exogenous internal control that was then quantified using a specific PCR reaction; this control was not 
intended for normalizing for the sputum content. 
 
Deep sequencing profiling of the 16S rDNA and data processing 
Deep sequencing to identify the content and structure of bacterial community targeted the V4 region of 
the 16S rRNA gene and was performed on a MiSeq sequencer with a 2x250 bp sequencing kit (Illumina, 
San Diego, CA, USA). Data were processed using the tools QIIME (Caporaso et al. 2010) and Mothur 
(Schloss et al. 2009). The process is described in detail in supplementary material, S2.1 and S2.2. To 
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control the sequencing process and subsequent analysis steps, an artificial Mock Community was 
sequenced along with the samples (courtesy of BEI Resources, NIAID, NIH; Genomic DNA from 
Microbial Mock Community B - Even, Low Concentration - v5.1L, for 16S rRNA Gene Sequencing, 
HM-782D). All samples including the Mock Community and negative controls were sequenced in 
triplicate, with each replicate prepared in a separate PCR plate. 
 
Conversion of data from 16S rDNA relative quantity to absolute quantities and specific PCR 
To estimate the absolute quantities of individual taxonomic units per µL DNA, we used the quantification 
results of the overall 16S rDNA content (supplementary material S2.3). To validate the above 
estimations of absolute quantity, we checked the following pathogens by specific quantitative PCR in 
real-time format: Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae and three 
members of the Streptococcus mitis group (reaction detecting S. oralis, S. mitis, and S. infantis) 
(supplementary material S2.4). 
 
The clinical and sequencing data as well as generic and specific PCR results have been deposited at the 
NCBI Sequence Read Archive (SRA) under project ID PRJNA339813; the study ID for the sample data 
is SRP083112.  
 
Diversity metrics, markers of inflammation and statistical analysis 
Alpha diversity was measured based on an OTU table normalized for 10,000 reads per sample by several 
indices (Observed species, Chao1, ACE, Shannon, Simpson, Inverse Simpson and Fisher; paired t-test).  
 
For analyses based on relative quantity, operational taxonomic units (OTUs) were clustered based on 97% 
similarity and filtered for being present in at least 5% of samples by at least 50 reads. The dominant 
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pathogen in each sample was defined as the one exceeding by at least two times the relative abundance of 
the second most abundant taxon (Carmody et al. 2013; Coburn et al. 2015).  
 
Species richness and evenness was compared using Shannon index between groups of samples from 
patients positive and negative for markers of inflammation: the upper normal limits were 13 x 109/L 
WBC and 8 mg/L CRP. The effect of antibiotic treatment on the total bacterial load and on absolute 
concentrations of abundant taxa was assessed using the Wilcoxon paired test with the Bonferroni 
adjustment for multiple comparisons, and the associations with clinical outcomes (FEV1 % predicted, 
WBC count, CRP) were assessed using generalized estimating equations in models which accounted for 
the repeated character of measurements. Analyses were performed using R package version 3.2.2 (R Core 
Team 2016) and the phyloseq package (McMurdie and Holmes 2013). 
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Results 
To analyse both the overall bacteriome composition and the quantity of its most abundant individual 
species, we exploited features of two different molecular approaches. While the taxa identification with 
their relative abundance was obtained by the 16S rDNA profiling using next generation sequencing 
(NGS), the absolute quantity of selected taxa was determined by using either a species-specific RQ-PCR 
[P. aeruginosa, S. aureus, H. influenzae and part of the Streptococcus mitis group (S. oralis, S. mitis, S. 
infantis)], or for less traditional CF-related pathogens, a product of relative abundance from 16S rDNA 
profiling with quantity from 16S rDNA panbacterial RQ-PCR. The results obtained by both approaches 
are summarized in Figure 1 A - D.  
 
Bacterial taxa change upon antibiotic therapy in both absolute and relative quantities 
The 16S rDNA triplicates of each sample were inspected for consistency using clustering graphs and 
merged, yielding between 48,641 and 194,050 sequences per sample (interquartile range 25,179 - 38,663; 
median 29,206). The total number of 824 OTUs were generated, many of them belonging to well-known 
CF pathogens, such as Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, 
Stenotrophomonas maltophilia and Achromobacter xylosoxidans. The first 11 taxa ranked by overall 
relative abundance are listed in Table 1, where their quantities are compared before and after the therapy. 
S. aureus was the most abundant pathogen in our samples, followed by P. aeruginosa. The effect of anti-
pseudomonal antibiotics on the relative 16S rDNA profiles as well as on absolute quantities was 
significant yet heterogeneous among individual taxa (Figures 2, Supplemental Figure S1, Figure 2). 
We noted a substantial decrease in the total bacterial load following antibiotic therapy (p = 0.001, Figure 
1C); this decrease was most profound in the samples where S. aureus or P. aeruginosa dominated. 
 
The absolute quantity of S. aureus measured by species-specific PCR showed a constant and significant 
decrease (Figure 2, Pcorrected = 0.03) and responded well to anti-pseudomonal treatment with post-
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antibiotic quantities that were often undetectable. The 16S rDNA profiling showed that S. aureus was 
dominant in pre-antibiotic samples from five courses of antibiotic therapy but remained the most 
abundant only in two of them following antibiotic therapy (Figure 2A), again indicating a profound 
response to antibiotic treatment. However, in two post-antibiotic samples (P4 course 2, P8 course 2), 16S 
rDNA profiling showed an increase in relative abundance of Staphylococcus spp. (comprising S. aureus, 
S. epidermidis, and S. hominis), while species-specific PCR targeting only S. aureus was negative 
(Figure 2A). This implies that S. epidermidis and/or S. hominis were responsible for this increase, as the 
V4 region of the 16S rRNA gene is identical for the three species, and they cannot be distinguished by the 
NGS method alone.  
 
P. aeruginosa was ranked second in quantity after S. aureus and was detected in 8 courses of antibiotic 
therapy by NGS and in 11 courses by species-specific PCR (Figure 2B). P. aeruginosa dominated the 
lung bacteriome in three of eight pseudomonas-positive pre-antibiotic samples and in three of seven post-
antibiotic samples (Table 1). P. aeruginosa was susceptible to antibiotics with a decrease in its absolute 
quantity in most cases (7 of 11 courses, Figure 2B). However, overall changes in P. aeruginosa quantity 
seemed to be dependent on its proportion in the bacteriome: two courses of antibiotic therapy (P7 course 
2, P9 course 1) in patients, whose samples were not dominated by P. aeruginosa, resulted in almost no 
change in its absolute quantity after antibiotic treatment. Furthermore, in two courses (P2 course 2, P6 
course 1) both the absolute and relative quantities of P. aeruginosa significantly increased despite the fact 
that in-vitro antibiotic susceptibility tests showed that it was  susceptible to the antibiotics used (Table 
S2). In both cases P. aeruginosa was not a dominant species in the pre-antibiotic sample.  
  
In addition to P. aeruginosa and S. aureus, other traditional CF pathogens were also found in the pre-
antibiotic samples. H. influenzae and A. xylosoxidans were both dominant in the pre-antibiotic samples 
(Figure 2, Figure S1 C), and both responded well to anti-pseudomonal treatment (Pcorrected for H. 
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influenzae = 0.055). By contrast, S. maltophilia was dominant only after antibiotic therapy and the 
increase with therapy was observed also in absolute numbers(Figure 1B). Several members of the 
Streptococcus mitis group (S. oralis, S. mitis, and S. infantis) detected by group-specific real-time PCR 
also showed a significant and consistent absolute decrease with antibiotic treatment (Pcorrected = 0.003) 
(Figure S1 D).  
 
Exploration of alpha diversity 
Antibiotic therapy for pulmonary exacerbations was borderline-associated with a decrease in the 
complexity of the lung bacteriome (Supplementary Figure S2). This tendency towards the decrease in 
diversity was indicated by some alpha (within-sample) diversity indices (Observed species, praw = 0.03, 
Chao1, praw = 0.05, and ACE, praw = 0.03, Fisher, praw = 0.022; paired t-test), but in contrast, the Shannon 
and Simpson diversity indices, often used for their ability to also distinguish the evenness of the species 
distribution, did not appreciably change (praw = 0.89, praw = 0.74, respectively).  
 
Association with clinical markers, and with the dominant pathogens 
Species richness measured by Shannon index had a borderline-significant tendency towards inverse 
association with CRP, but not with increased leukocytes (Supplemental Figure S2 - B). A significantly 
lower Shannon index was found in samples with dominant pathogens among the 'traditional' CF-related 
bacteria (P. aeruginosa, S. aureus, A. xylosoxidans, H. influenzae, S. maltophilia), P < 10-5 when 
compared to samples without a dominant species, or with samples dominated by other organisms. The 
Shannon index also decreased with decreasing values of FEV1%, p = 0.003 (Supplemental Figure S2 - 
B). 
 
We then tested the association of the 11 most abundant taxa (Table 1) with a change in markers of 
clinical improvement. The 11 taxa were chosen based on their presence as a dominant pathogen or based 
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on their average relative abundance in all samples higher than 5%. The following clinical parameters 
were tested: FEV1 % predicted, as a parameter of lung function, and WBC count and CRP, as markers of 
inflammation. An association with improvement of lung function was found for Granulicatella sp. 
(present in five pre-antibiotic samples and six post-antibiotic samples); in the regression model, a ten-fold 
increase in its quantity was associated with an increase in the FEV1 of 5.5 % (p = 0.004). We also 
detected a significant association of the total bacterial load with the WBC count; a ten-fold decrease in the 
total 16S rDNA load was associated with a decrease in WBCs by 2 x 109/L (p = 0.007). No associations 
with CRP levels were noted.  
 
Correlation between specific PCR detection and 16S rDNA profiling 
To assess the accuracy of calculated absolute quantities (obtained by the conversion of the taxon 
proportion from the NGS 16S rDNA profile, multiplied by the total 16S rDNA load from generic real-
time PCR), these values were directly compared to quantities from species-specific real-time PCR. The 
comparison for P. aeruginosa is illustrated in Supplementary Figure S6. Although the overall results 
acceptably correlate (R = 0.92, p < 10-10; Spearman rank correlation test), a discrepancy can be noted in 
samples found negative by specific PCR: here the 16S rDNA NGS profiling reports a low, but positive 
signal. Similarly to P. aeruginosa, in S. aureus and H. influenzae the absolute quantities obtained by PCR 
and NGS correlate generally well (p < 10-6, Spearman rank correlation test), but NGS yielded several 
false-positive samples.  
 
Relative and absolute quantification 
Presented results were obtained by using two different approaches, the relative quantity resulting from 
16S sequencing and absolute quantity obtained by either species-specific PCR or by a conversion of 16S 
results with the total 16S load. Inspecting the same pairs of sputum samples, the results by both 
approaches differed, as illustrated in Figure 2: in 2 antibiotic courses species-specific PCR reported a 
 12 
 
decrease in quantity of P. aeruginosa while an increase in relative quantity was reported by 16S 
sequencing(courses P2c1, P9c1). Similar inconsistency was noted for S. aureus (course P9c1, courses 
P4c2 and P8c2 reported an increase of relative abundance of S. epidermidis/ hominis) and for other 
species (data not shown).  
 
Contaminating signals 
The analysis of multiple negative controls indicated that the signal of E. coli most likely originated from 
PCR chemicals rather than from the sputum itself (Supplementary Figure S3). The signal of Escherichia 
coli, which was found in all samples in average proportion of 2.4%, also seemed to change with the 
antibiotic therapy: it consistently increased in relative quantity in all post-antibiotic sputum samples 
(Supplementary Figures S4 - A, S5). After a conversion of E.coli 16S profiles to absolute quantity 
values by multiplication with the total 16S load, an actual decrease of quantity was noted in 9 courses of 
antibiotic therapy (Supplementary Figures S4 - B) and the change in E. coli absolute quantity seemed to 
inversely copy the change in absolute bacterial concentration (Supplementary Figure S5, S4C).  
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Discussion 
Our study assessed the lung bacteriome profiles in sputum samples from paediatric patients chronically or 
intermittently infected with P. aeruginosa. Samples were taken at the beginning and at the end of 
intravenous antibiotic treatment either as a part of maintenance treatment or for treating an acute 
exacerbation. Both the total bacterial load and the composition of the sputum 16S rDNA profile changed 
in all sputum pairs. Apart from detection of changes in the bacteriome we also compared different 
methods used for studying lung microbes.  
 
The total bacterial load, measured by quantitative real-time PCR of the 16S rDNA, significantly 
decreased following antibiotic therapy; this decrease was as great as four orders of magnitude over two 
weeks and was significantly associated with a decrease in WBCs. However, the total bacterial load 
change was not associated with changes in lung function (FEV1 %), which can be explained by the degree 
of diversity among individual lung microbiota that contained species ranging from obligate CF pathogens 
to bacteria potentially beneficial to CF patients. The rapid and profound response of the total bacterial 
load to the i.v. therapy may indicate plasticity of paediatric lung bacteriome; this observation is in 
contrast to data published in adults (Price et al. 2013; Zemanick et al. 2013).  
 
Diversity indices enabled us to observe the complexity of the bacteriome. The most important driver of 
alpha (within-sample) diversity was the dominant pathogen, as has been reported by previous studies 
(Carmody et al. 2015; Coburn et al. 2015; Filkins et al. 2012). Communities dominated by streptococci 
were associated with significantly higher diversity than those dominated by Pseudomonas or 
Staphylococcus. Furthermore, Streptococcus-driven communities are also known to be very stable not 
only during periods of clinical stability but also during periods of exacerbation (Carmody et al. 2015), 
which was true e.g. for all three courses of antibiotic therapy experienced by patient 5 (Figure 2).  
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Interestingly, higher species richness was associated with better clinical status, as measured by FEV1 and 
marginally also by CRP as a marker of inflammation. Similar association was observed in other studies 
(Coburn et al. 2015; Fodor et al. 2012; van der Gast et al. 2014; Zhao et al. 2012).We believe that the 
richer species distribution in such communities (which are devoid of classical CF pathogens) can better 
mimic the transient polymicrobial nature of healthy lungs and can be a marker of less severe lung disease 
in CF patients, as previously described (Zhao et al. 2012). Alpha diversity indices of Observed species, 
Chao1 and ACE significantly decreased with therapy, whereas the Shannon and Simpson indices did not. 
The latter two represent richness as well as evenness, and their usage has been encouraged by other 
studies (Carmody et al. 2015; Carmody et al. 2013; Price et al. 2013; Zemanick et al. 2013).  
 
A considerable response to anti-pseudomonal therapy was noted for all detected CF-related pathogens, 
such as P. aeruginosa, S. aureus, H. influenzae, and A. xylosoxidans, confirming that anti-pseudomonal 
treatment was effective against a broad spectrum of pathogens. In two instances (courses P2c2 and P6c1), 
other pathogens (H. influenzae, S. aureus) were profoundly reduced, whereas P. aeruginosa increased 
both in relative proportion and absolute numbers despite its in vitro sensitivity to the administered 
antibiotics. The reason for this is not at hand – heterogeneity of P. aeruginosa strains which co-exist in 
the lungs probably plays a role (Winstanley et al. 2016). A similar relative increase of the bacterium 
during antipseudomonal therapy was reported by Daniels et al. (Daniels et al. 2013) using a T-RFLP 
method; however, the authors reported no absolute bacterial quantities; therefore, their results are difficult 
to compare to the present observations.  
 
Apart from these commonly detected pathogens, we observed a number of species that are less often 
regarded to be part of traditional CF microbiology, especially anaerobes. These species are becoming a 
focus of research for their relatively frequent occurrence as dominant pathogens (Carmody et al. 2015; 
Price et al. 2013) even at the time of pulmonary exacerbations (Zemanick et al. 2010) when the 16S 
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rDNA profiling of CF respiratory samples is applied. Proving causative links has been extremely 
complicated because of their concurrent occurrence in the upper airways (Goddard et al. 2012) and the 
lack of routine culture-based results. Interestingly, the species-specific PCR showed that several members 
of the Streptococcus mitis group (S. oralis, S. mitis, and S. infantis) significantly decreased in quantity 
upon antibiotic therapy. Streptococci found in the sputum samples have also been often identified in oral 
flora (Filkins et al. 2012), which complicates our understanding their role in CF lungs, as they might 
originate from upper airways. This effect is especially true for children because of their limited ability to 
expectorate sputum. However, many studies support the presence of streptococci and other non CF-
related species in lower airways and their potential role in CF lung disease, as reviewed by Caverly et al. 
(Caverly et al. 2015).  
 
At present, we have no plausible explanation for the positive association of Granulicatella spp. with 
increased FEV1. The genus Granulicatella was established in 2000 and previously belonged to 
nutritionally variant streptococci (Cargill et al. 2012). The genus is a component of the normal oral 
microflora, similar to the viridans streptococci that were also found in CF lungs (Cargill et al. 2012; 
Filkins et al. 2012). The genetic relatedness of Granulicatella to these streptococci can also be indicative 
of its association with better lung function, similar to what was observed for streptococci (Filkins et al. 
2012). To the best of our knowledge, no association between clinical status and Granulicatella has been 
described, so the finding merits further investigation. Indeed, relationships similar to what we detected, 
especially for non-CF related pathogens, are known from the literature, but no consistent conclusions can 
be drawn (Carmody et al. 2013; Zemanick et al. 2013). Interestingly, Granulicatella adiacens was found 
to be associated with the lung cancer (Cameron et al. 2017), which may further support its utility as a 
marker organism in various processes.    
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One strength of our study is the focus on children, an age group often underrepresented in the literature 
regarding the lung bacteriome. Similar to other authors, we believe that bacteriome features are different 
in children compared to adult patients. A study by van der Gast et al. (van der Gast et al. 2014) that 
included children and adults with different chronic lung diseases revealed a high degree of clustering 
within the paediatric cohorts; however, the adults clustered neither within the adult cohort nor with their 
paediatric counterparts. Interestingly, the most common species detected in paediatric patient cohorts 
were also found in four healthy children included in that study. Children and adults are also reported to 
differ with regard to species richness; higher species richness is associated with better lung function in 
children (Coburn et al. 2015; van der Gast et al. 2014). Antibiotic treatment for pulmonary exacerbation 
represents the key factor for species turnover, as described previously (Cuthbertson et al. 2015), and is 
therefore an important variable in shaping the lung bacteriome.  
 
A second strength of our study is that we determined both relative and absolute quantities of bacterial 
species. 16S rDNA profiling, which confers the information about relative quantity only, was utilized for 
identification of taxa and to determine their fraction in the bacteriome. However, the real effect of 
antibiotics on bacterial mass cannot be revealed unless absolute quantities are also known. The situation 
is exemplified in Figure 1, where an increase of relative proportion of bacteria was noted while the 
“true”, absolute quantity reported a decrease in several instances. Although most studies describe 
bacterial lung communities by relative abundance (Coburn et al. 2015; Cuthbertson et al. 2015; van der 
Gast et al. 2014), few have also evaluated the absolute quantity (Carmody et al. 2015; Zemanick et al. 
2013). We used specific real-time PCR to quantify not only the overall bacterial load but also the four 
most important groups of CF pathogens. The use of absolute quantities also helps resolve the weak 
contamination of PCR polymerases by bacterial DNA. It is known that some recombinant polymerases 
are weakly contaminated by E. coli 16S rDNA or other bacterial DNA (Spangler et al. 2009). This 
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contamination emerges in the bacteriome profiles only if there is little bacterial DNA in the sample; the 
contaminant proportion, therefore, logically increases in post-antibiotic samples (Figure S4).  
 
The use of two methodological approaches also revealed the difference in the true detection thresholds 
and specificity: species-specific PCR performed better than NGS 16S profiling. The NGS profiling 
produces several false low-positive signal, probably caused by a signal cross-bleed among samples. This 
is a known phenomenon caused by imperfection in the currently available sample indexing strategy, and 
has been reported by others and us (Kircher et al. 2012; Kramna et al. 2015). Furthermore, low abundance 
bacteria may be diminished in the 16S profiles - more abundant species are amplified preferentially as 
compared to species present in low quantities (Gonzalez et al. 2012).  
 
Among the limitations, we do not know whether we detected predominantly live bacteria, or also 
leftovers of DNA from dead cells. Detecting DNA from dead bacterial cells may lead to underestimation 
of the antibiotic effect on taxa, as reported by Rogers et al. (Rogers et al. 2010). Given that the dynamics 
of bacteriome profile changes were extreme (several orders of magnitude quantity changes), we believe 
that the majority of the signal came from live organisms. Secondly, the use of chemicals such as 
propidium monoazide (PMA) enables one to block the dead cell signal; however, numerous other issues 
connected with the use of PMA may act as a source of bias, as reviewed in (Caverly et al. 2015). The 
quantitative PCR efficacy may also marginally differ among species, as the bacteria do not have equal 
copy numbers of the 16S rRNA genes, and primers themselves may also vary in efficacy; the assessment 
of calibration curves, however, suggested that this source of variation is not prominent. Furthermore, we 
used lysostaphin, but no other enzymes in the DNA extraction protocol. Rather than sole use of 
lysostaphin, it seems that the present protocols tend towards enzyme cocktails, although their composition 
has not been agreed upon universally (Bera et al. 2005). A cocktail of enzymes might have further 
improved the lysis of bacterial walls (Bag et al. 2016; Yuan et al. 2012).  
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Furthermore, the use of the sole V4 region was not be able to distinguish among certain groups of 
pathogens, such as for staphylococci: S. aureus, S. epidermidis, S. hominis. While S. aureus is known 
pathogen, other two have been reported as comensals on the skin (Otto 2009; Weinstein et al. 1998) and 
have not normally been linked with a lung condition. Most of the time they appear as sample 
contaminants (Otto 2009; Weinstein et al. 1998), so the presently available data cannot resolve whether 
the increase in their quantity observed in treatment courses P4c2 and P8c2 are genuine or not.   
 
Finally, our data have limited generalizability, primarily because of the limited patient sample size, 
frequency of sampling and a gender imbalance. It was previously reported that females are more prone to 
a progression of pseudomonal infection than males (Chotirmall et al. 2012). We also did not take into 
account the fact that the virulence of individual taxa likely changes when crossing a certain quorum 
(Ulrich et al. 2010). At last, our results monitor only the period of antibiotic treatment and we do not 
know what happened later during the recovery, as studied elsewhere (Cuthbertson et al. 2015; Price et al. 
2013).   
 
In conclusion, our study exemplifies the heterogeneity of changes in the composition of the paediatric 
lung bacteriome following intravenous therapy for chronic or intermittent infection with P. aeruginosa. 
This study supports the use of absolute bacterial counts derived from the combination of total bacterial 
load quantification by real-time PCR and 16S rDNA profiling using next generation sequencing. Finally, 
we observed a possible novel association of Granulicatella sp. with an improvement in lung function.  
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Table 1: Top 11 bacterial taxa in samples before and after antibiotic therapy 
  Samples before antibiotic treatment Samples after antibiotic treatment 
Bacterial species a 
The average 
relative 
abundance (%) 
The number of 
occurrences  
(N, %) d 
The number of 
samples where species 
was dominant (%) e 
The average 
relative 
abundance (%) 
The number of 
occurrences  
(N, %) d 
The number of samples 
where species was 
dominant (N, %) e 
Staphylococcus spp. (S. aureus, S. 
epidermidis, S. hominis)b 
 
 
30 10 (63) 5 (31), all of them 
being S. aureus 
21 8 (50) 4 (25), of these: 
2 S. aureus 
2 S. epidermidis or 
hominis 
Pseudomonas aeruginosa 15 8 (50) 3 (19) 18 7 (44) 3 (19) 
Streptococcus mitis group (S. oralis, S. 
dentisani, S. mitis, S. infantis, S. 
tigurinus) 
9.5 12 (75) 2 (6) 6.9 9 (56) 0 
Veillonella dispar 8.0 12 (75) 1 (6) 5.7 6 (38) 0 
Rothia mucilaginosa 4.5 8 (50) 0 6.6 9 (56) 0 
Prevotella melaninogenica 4.3 10 (63) 0 2.9 6 (38) 0 
Stenotrophomonas maltophilia 0.08 0 0 6.6 2 (13) 1 (6) 
Granulicatella spp. (G. adiacens, G. 
balaenopterae) 
1.1 5 (31) 0 5.2 6 (38) 1 (6) 
Streptococcus salivarius spp. (S. 
thermophilus, S. salivarius) 
3.7 8 (50) 0 1.7 4 (25) 0 
Haemophilus spp. (H. influenzae, H. 
haemolyticus)c 
5.09 2 (13) 1 (6) 0.19 1 (6) 0 
Achromobacter xylosoxidans 3.8 1 (6) 1 (6) 0.06 0 0 
Other species with average relative 
abundance above 1% - 4.9% 
Actinomyces odontolyticus, Escherichia coli, Prevotella sp. oral taxon g70, Scardovia inopinata f0304, Lactobacillus spp. (L. 
paracasei, L. casei), Parvimonas micra, Catonella morbi ATCC 51271, Prevotella nanceiensis, Fusobacterium necrophorum 
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Taxa are ordered according to their overall average relative abundance. Taxa were chosen based on their 
presence as a dominant pathogen or based on their average relative abundance higher than 5%. Further 
taxa with an average relative abundance of 1% to 4.9% are noted in the last line of the table.  
 
(a) Several taxa were identifiable only as a group of species because of the limited discriminating ability 
of the variable region 4 of the 16S rRNA gene. S. aureus and H. influenzae were further distinguished 
from the other species within their OTU groups by specific PCR.  
(b) This OTU group includes the three listed species. S. aureus was further identified in samples by 
specific real-time PCR targeting the nuc gene. 
(c) Identified as H. influenzae by specific PCR. 
(d) Species present in the sample by at least 1% of relative abundance. 
(e) Dominance is defined as being at least 2x more abundant than the second most abundant species 
(Carmody et al. 2013; Coburn et al. 2015) 
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Figure Legends and Footnotes 
Figure 1 A - D: The effect of antibiotic treatment on the composition of the lung bacteriome. 
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A sample after a course of antibiotic therapy was compared to its paired sample before therapy. Changes in 
the sputum bacteriome were assessed by three methods.  
 
Panel (A) - the relative 16S rDNA profiles are used for calculations of the fold-changes, disregarding the 
overall quantity of bacteria in the sputum sample.  
Panel (B) - the fold-changes are calculated from absolute quantities of each taxa, which were derived from 
the proportion of the taxon within the 16S rDNA profile multiplied by the absolute concentration of all 
bacteria in µL of sputum, as determined using real-time PCR.  
Panel (C) - the total bacterial 16S rDNA concentration, assessed using real-time PCR with generic primers 
in pre-antibiotic sample (red circle) and its corresponding post-antibiotic sample (blue circle). The arrow 
shows the direction and magnitude of response. 
Panel (D) - fold-change in the total bacterial concentration between the paired sputum samples taken before 
and after the antibiotic therapy. Identical data as in Panel C, presented in relative scale.  
 
Panels A and B show 16 taxa with the highest relative abundance in the overall sputum bacteriome; the last, 
E. coli, is a product of bacterial contamination of the polymerase utilized for 16S rDNA amplification 
(Spangler et al. 2009). The colour codes show the decadic logarithm of the relative change between the 
paired samples before and after the antibiotic treatment (blue for a decrease with treatment, red for an 
increase with treatment, white for no appreciable difference). Rows - individual bacterial taxa, ordered by 
the average relative share in sputum. Columns - individual episodes = courses of antibiotic therapy, coded 
by numeric identification of the patient, and the sequential identification of the course. 
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Figure 2: Changes in absolute and relative quantity of two most abundant pathogens 
 
 
Upper graphs summarize the difference in absolute quantity (gene copies per µL) obtained by a species-
specific PCR. Lower graphs show the relative quantities (%) from 16S rDNA sequencing. The pre- versus 
post-antibiotic samples are coded by colours of the bar .  
 
(A) S. aureus and its changes over the courses of antibiotic treatment. While the specific detection shows a 
good response to antibiotic treatment, the 16S rDNA sequencing (lower panel) in antibiotic courses P4c2 
and P8c2 documents an increase in the proportion of reads: the V4 region of the rDNA gene does not allow 
distinguishing S. aureus from S. epidermidis and S. hominis, this signal therefore comes from either of the 
latter two species. 
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(B) P. aeruginosa and its changes over the courses of antibiotic treatment. Species-specific PCR had a lower 
detection threshold than 16S rDNA sequencing.  
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Figure 3: Changes in relative abundance of the top 11 taxa assessed by NGS  
 
 
Each pair of bars represents one course of antibiotic therapy; the first bar represents a sample taken at the 
beginning of antibiotic therapy (referred to as “before”) and the second is taken at the end of the therapy 
(referred to as “after”). Patient and the course of antibiotic treatment are identified at the top of the bar.  
 
Each colour represents the fraction of one of the top11 OTUs. These 11 were selected because of their 
presence as a dominant pathogen in any of the samples or if their average relative abundance exceeded 5%. 
Several OTUs were identified only as a group of taxa that could not be distinguished by the V4 region of the 
16S rRNA gene - therefore potential species of this OTU are listed.  
 
The sum of remaining OTUs is shown in light blue, and they fill each bar up to 100%. 
